BioCentury | Dec 7, 2018
Company News

Chinese biopharma stocks plummet after centralized tendering report

Chinese biopharma stocks tumbled Dec. 6 in the wake of media and analyst reports suggesting that pricing discounts on generic drugs under China's centralized procurement program were greater than expected. State-owned Shanghai Securities News reported...
BioCentury | Dec 7, 2018
Company News

Chinese biopharma stocks plummet after centralized tendering report

Chinese biopharma stocks tumbled Thursday in the wake of media and analyst reports suggesting that pricing discounts on generic drugs under China's centralized procurement program were greater than expected. State-owned Shanghai Securities News reported significantly...
BioCentury | Feb 8, 2016
Company News

Taisho Pharmaceutical Holdings, Teijin sales and marketing update

...Teijin launched Loqoa Tape in Japan to treat pain and inflammation in patients with osteoarthritis (OA). Teijin...
...OA). Teijin has co-marketing and distribution rights in Japan to the transdermal NSAID patch containing S-flurbiprofen...
BioCentury | Dec 8, 2011
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Thioredoxin; NF-kB In vitro and mouse studies suggest a class of NSAID analogs could help treat cancer. Synthesis and in vitro testing identified diphosphorylated...
BioCentury | Sep 28, 2009
Clinical News

NicOx preclinical data

In a rat model of inflammation, HCT 1026 significantly reduced inflammation vs. placebo (p<0.05), similar to flurbiprofen. HCT 1026 also showed greater gastrointestinal tolerability than flurbiprofen. In rabbits, HCT 1026 decreased blood pressure and increased...
BioCentury | Jul 20, 2009
Company News

Amdipharm plc, Recordati sales and marketing update

Amdipharm granted Recordati exclusive rights to market TransAct local action transcutaneous (LAT) in Italy and Portugal for symptomatic relief of localized pain involving the musculoskeletal system. The transdermal patch containing 40 mg flurbiprofen had sales...
BioCentury | Feb 16, 2009
Strategy

Lundbeck's Ovation

With the patent expiry of its lead products looming for H. Lundbeck A/S , the Danish pharma's acquisition of Ovation Pharmaceuticals Inc. is more about top-line growth than establishing a U.S. bridgehead. While it is true...
BioCentury | Aug 4, 2008
Product Development

Elan's Phase III dash

Final Phase II data released last week from a Phase II trial of bapineuzumab in Alzheimer’s disease raised red flags, especially after Elan Corp. plc and partner Wyeth had put a positive spin on preliminary...
BioCentury | Jul 7, 2008
Finance

2Q approvals

2Q approvals Selected second quarter product approvals. The list does not include an FDA approvable letter for Zentase pancrealipase capsules to treat exocrine pancreatic insufficiency from Eurand (NASDAQ:EURX). While not a full approval, the company...
BioCentury | Jul 7, 2008
Strategy

Flurizan’s failure adds value

Myriad Genetics Inc. and partner H. Lundbeck A/S were surely disappointed when Flurizan tarenflurbil failed a Phase III trial to treat mild Alzheimer’s disease. But investors made it very clear that they would rather the...
Items per page:
1 - 10 of 80